Hesperidin protects against cisplatin-induced cardiotoxicity in mice by regulating the p62–Keap1–Nrf2 pathway
Open Access
- 21 March 2022
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 13 (7) , 4205-4215
Abstract
Hesperidin (HES) is an abundant and economical dietary bioflavonoid, and it has several pharmacological properties such as antioxidant activity and powerful cardiac protection. However, HES protection against cisplatin (CP)-induced cardiotoxicity and its mechanism have not been fully clarified. The current study was performed to further elucidate the mechanism of HES against CP-induced cardiotoxicity. Mice were orally administered HES (100 or 300 mg kg−1 day−1) for 7 consecutive days and then injected intraperitoneally (i.p.) with CP (5 mg kg−1) on days 3 and 6. On day 8, mice were anaesthetised with sodium pentobarbital (50 mg kg−1, i.p.), and blood and heart samples were collected for analysis. HES treatment reduced CP-induced cardiac pathologic damage and leakage of the myocardial markers cardiac troponin I (cTnI), creatine kinase (CK), and lactate dehydrogenase (LDH). HES treatment reduced levels of reactive oxygen species (ROS) and malondialdehyde (MDA), which is an oxidative product, and increased antioxidant marker levels including superoxide dismutase (SOD), catalase (CAT), and glutathione (GSH). HES also reduced the CP-induced release of the inflammatory factors tumour necrosis factor (TNF)-α and interleukin (IL)-6. Additionally, HES treatment up-regulated the expression of anti-apoptotic protein Bcl-2 and down-regulated the expression of pro-apoptotic proteins Bax and Caspase-3. HES treatment also improved the expression of pathway proteins p62 and Nrf2 and inhibited the increase in CP-induced Keap1 expression. Thus, HES may provide protection against CP cardiotoxicity through inhibiting oxidative stress, inflammation, and apoptosis, which may contribute to activation of the p62–Keap1–Nrf2 signalling pathway. These findings suggest that HES may be a promising protective agent against CP cardiotoxicity in future anticancer clinical practice.Keywords
This publication has 47 references indexed in Scilit:
- Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategiesEuropean Journal of Pharmacology, 2011
- Cisplatin compromises myocardial contractile function and mitochondrial ultrastructure: Role of endoplasmic reticulum stressClinical and Experimental Pharmacology and Physiology, 2010
- Nrf2:INrf2 (Keap1) signaling in oxidative stressFree Radical Biology and Medicine, 2009
- Temporal Gene Expression Profiling Indicates Early Up-regulation of Interleukin-6 in Isoproterenol-induced Myocardial Necrosis in RatToxicologic Pathology, 2008
- Citrus Flavonoids in Fruit and Traditional Chinese Medicinal Food Ingredients in ChinaPlant Foods for Human Nutrition, 2006
- Propionyl-l-carnitine prevents the progression of cisplatin-induced cardiomyopathy in a carnitine-depleted rat modelPharmacological Research, 2006
- Nrf2 signaling in coordinated activation of antioxidant gene expressionFree Radical Biology and Medicine, 2004
- Cardiotoxicity of cytotoxic drugsCancer Treatment Reviews, 2004
- PROTECTIVE EFFECTS OF VITAMIN C AGAINST CISPLATIN-INDUCED NEPHROTOXICITY AND LIPID PEROXIDATION IN ADULT RATS: A DOSE-DEPENDENT STUDYPharmacological Research, 2000
- Taurine Protects against Oxidant-Induced Lung Injury: Possible Mechanism(s) of Action1994